Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 53: 1254-1263, 2007. First published May 17, 2007; 10.1373/clinchem.2007.085563
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 085563.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2007.085563v1
53/7/1254    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kam, R. K.T.
Right arrow Articles by Sung, J. J.Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kam, R. K.T.
Right arrow Articles by Sung, J. J.Y.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2007;53:1254-1263.)
© 2007 American Association for Clinical Chemistry, Inc.


Proteomics and Protein Markers

High-Throughput Quantitative Profiling of Serum N-Glycome by MALDI-TOF Mass Spectrometry and N-Glycomic Fingerprint of Liver Fibrosis

Richard K.T. Kam1,2, Terence C.W. Poon1,2,3,a, Henry L.Y. Chan2,3, Nathalie Wong4, Alex Y. Hui2 and Joseph J.Y. Sung2,3

1 Li Ka Shing Institute of Health Sciences, 2 Department of Medicine and Therapeutics, 3 Centre for Emerging Infectious Diseases, and 4 Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR.

aAddress correspondence to this author at: Li Ka Shing Institute of Health Sciences, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, N.T., Hong Kong SAR. Fax 852-2648-8842; e-mail tcwpoon{at}cuhk.edu.hk.

Background: The use of MALDI-TOF mass spectrometry (MS) in quantitative glycan profiling has not been reported. In this study, we attempted to establish a high-throughput quantitative assay for profiling serum N-glycome, and we applied the new assay to identifying serum N-glycans for diagnosis of liver fibrosis and cirrhosis.

Methods: N-glycans from whole serum proteins in 2 µL serum were released by enzymatic digestion, cleaned up by hydrophilic chromatography, and subsequently quantitatively profiled with a linear MALDI-TOF MS system, which was originally designed for quantitative proteomic profiling. Serum N-glycome profiles from 46 patients with chronic hepatitis B infection and with different degrees of liver fibrosis were examined.

Results: The intra- and interassay CVs of peak intensities of the standard N-glycans were <8% and <17%, respectively. When the assay was applied to the analysis of serum N-glycome profiles, 17 peaks were found to be potential biomarkers for detection of liver fibrosis/cirrhosis. Linear regression analysis revealed that 4 peaks of 1341.5, 1829.7, 1933.3, and 2130.3 m/z (all P <0.005) had complementary value in detecting liver fibrosis and included them, but not any serological markers, in the diagnostic model. Leave-one-out cross-validation showed the diagnostic model could identify significant fibrosis (Ishak score ≥3) and cirrhosis (Ishak score ≥5), both at 85% accuracy.

Conclusion: This is the first study to illustrate the quantitative aspect of MALDI-TOF MS in N-glycome profiling and the first study to reveal the potential value of the serum N-glycan profile for identifying liver fibrosis.




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
K. D. Yang, W.-C. Chang, H. Chuang, P.-W. Wang, R.-T. Liu, and S.-H. Yeh
Increased Complement Factor H with Decreased Factor B Determined by Proteomic Differential Displays as a Biomarker of Tai Chi Chuan Exercise
Clin. Chem., January 1, 2010; 56(1): 127 - 131.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. J. Bennett
Untargeted Metabolomic Analysis Hits the Target
Clin. Chem., December 1, 2007; 53(12): 2037 - 2039.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.